FDA, GSK and Penmenvy

GSK’s Penmenvy meningococcal vaccine gains FDA approval
The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The integration of the MenABCWY vaccine into healthcare pra
Pentavalent Meningococcal Vaccine Penmenvy Gets FDA Approval
Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).
FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage recommendations on Feb. 26.
GSK’s 5-in-1 meningococcal shot wins FDA approval
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through 25 years old.
FDA Approves More Broadly Protective Meningococcal Vaccine
The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), according to a press release from GlaxoSmithKline (GSK).
GSK reports FDA approves Penmenvy 5-in-1 meningococcal vaccine
GSK (GSK) plc announced that the Food and Drug Administration has approved Penmenvy for use in individuals aged 10 through 25 years. The
FDA approves GSK’s pentavalent meningococcal vaccine
The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against five meningococcal serogroups, the company announced.The vaccine, branded as Penmenvy,
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to play catch-up after nabbing its own FDA approval.  | The company's Penmenvy combines components of its established MenB and MenACWY vaccines Bexsero and Menveo,
GSK’s Penmenvy wins FDA approval
UK pharma major GSK late Friday announced that the US Food and Drug Administration (FDA) has approved Penmenvy (meningococcal groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 years.
GSK gets meningitis vaccine green light from US FDA
US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake of Donald Trump's election for a second term as President.
pharmaphorum4d
GSK gets ready for its next big vaccine launch
GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...
BioSpace4d
FDA Issues Back-to-Back Vaccine Approvals as RFK Jr. Takes HHS Seat
The approvals come as Robert F. Kennedy Jr.—who has been critical of vaccines—takes leadership of the Department of Health ...
FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week (UPDATED)
The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...